Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) reached a new 52-week high during trading on Monday . The stock traded as high as $14.35 and last traded at $14.24, with a volume of 1685319 shares changing hands. The stock had previously closed at $13.33.
Silverback Therapeutics Price Performance
The stock has a market capitalization of $483.18 million, a price-to-earnings ratio of -5.54 and a beta of 0.60. The company has a 50-day simple moving average of $10.22 and a two-hundred day simple moving average of $9.22.
Silverback Therapeutics Company Profile
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Further Reading
- Five stocks we like better than Silverback Therapeutics
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- Energy and Oil Stocks Explained
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
